[1]PAN R.Cancer incidence and mortality:A cohert study in China[D].Nanjing:Nanjing Medical University,2017.[潘睿.中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[D].南京:南京医科大学,2017.]
[2]LANG JH.Gynaecological malignant tumor screening[J].Chinese Journal of Practical Gynecology and Obstetrics,2016,32(05):385-389.[郎景和.妇科恶性肿瘤筛查[J].中国实用妇科与产科杂志,2016,32(05):385-389.]
[3]ZOU CJ,LUO Q,WU MX,et al.Value of serum HE4 and CA125 in predicting poor prognosis of endometrial carcinoma[J].Maternal and Child Health Care of China,2018,33(08):1707-1710.[邹纯静,罗庆,吴谋喜,等.血清HE4和CA125预测子宫内膜癌患者不良预后的价值[J].中国妇幼保健,2018,33(08):1707-1710.]
[4]LIN YY,CHEN Y,HU MH,et al.The value of single and combined detection of HE4,CA125 and CA19-9 in the diagnosis of endometrial carcinoma[J].Chinese Journal of Clinical Laboratory Science,2014,32(06):471-473.[林莺莺,陈燕,胡敏华,等.HE4、CA125和CA19-9单项和联合检测在子宫内膜癌诊断中的价值[J].临床检验杂志,2014,32(06):471-473.]
[5]WANG LZ,LI T.Progress in the detection of human epididymal protein-4 and its clinical diagnosis[J].Chinese Journal of Clinical Laboratory Science,2018,36(07):517-519.[王莲子,李涛.人附睾蛋白4检测及其临床诊断应用的研究进展[J].临床检验杂志,2018,36(07):517-519.]
[6]Dewan R,Dewan A,Hare S,et al.Diagnostic performance of serum human epididymis protein 4 in endometrial carainoma:A pilot study[J].J Clin Diagn Res,2017,11(7):XC01-XC05.
[7]REN YF,ZHANG XL,WANG YH,et al.The detection of human epididymal secretory protein 4 (HE4) and carbo-hydrate antigen 125 (CA125) in patients with endometrial carcinoma and their clinical value[J].Modern Oncology,2018,26(09):1392-1395.[任艳芳,张秀玲,王玉红,等.子宫内膜癌患者血清人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)的检测及其临床价值[J].现代肿瘤医学,2018,26(09):1392-1395.]
[8]LI L,LUO YW,HE X,et al.Diagnostic value of combined detection of BMI and serum HE4,CA125 in patients with endometrial carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(05):91-94.[李玲,罗雅文,何霞,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91-94.]
[9]ZHAO LQ,CHEN X,CHEN L,et al.Differential diagnostic value of combined detection of serum HE4 and CA125 in patients with endometrial carcinoma from benign uterus tumor[J].China Oncology,2012,22(11):820-824.[赵灵琴,陈曦,陈鲁,等.人附睾分泌蛋白4和CA125联合检测在子宫内膜恶性肿瘤与子宫良性肿瘤鉴别诊断中的价值[J].中国癌症杂志,2012,22(11):820-824.]
[10]Leibowitz-Amit R,Templeton AJ,Omlin A,et al.Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer[J].Ann Oncol,2014,25(3):657-662.
[11]Koh CH,Bhoo-Pathy N,Ng KL,et al.Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer[J].Br J Cancer,2015,113(1):150-158.
[12]Yu L,Lv CY,Yuan AH,et al.Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer[J].World J Gastroenterol,2015,21(20):6280-6286.
[13]Proctor MJ,Morrison DS,Talwar D,et al.A comparison of inflammation-based prognostic scores in patients with cancer.A glasgow inflammation outcome study[J].Eur J Cancer,2011,47(17):2633-2641.
[14]Zahorec R.Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill[J].Bratisl Lek Listy,2001,102(1):5-14.
[15]Hong J,Mao Y,Chen X,et al.Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer[J].Tumour Biol,2016,37(3):4135-4142.
[16]HU D,MA L.Research on the correlation between preoperative NLR and prognosis of ovarian cancer[J].Modern Oncology,2018,26(17):2790-2793.[胡蝶,马玲.术前NLR与卵巢癌预后的相关性研究[J].现代肿瘤医学,2018,26(17):2790-2793.]
[17]LI W,WANG L,ZHANG JC,et al.Correlation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with the prognosis of endometrial carcinoma[J].Journal of Medical Postgraduates,2018,31(01):60-64.[李文,王璐,张军成,等.术前外周血中性粒细胞及血小板与淋巴细胞比值对子宫内膜癌患者预后的影响[J].医学研究生学报,2018,31(01):60-64.]